Clinical trials: Post Herpetic Neuralgia
Postherpetic Neuralgia
The Efficacy of MK-8291 in Participants With Post-herpetic Neuralgia (PHN) With Allodynia (MK-8291-012)
This study aims to determine whether MK-8291 is effective in reducing pain in participants with post-herpetic neuralgia (PHN) with allodynia.
- Trial name
- NCT02336555
- Testing
- MK-8291
- Volunteers
- 35 people
- Sponsor
- Merck Sharp & Dohme LLC
Post Herpetic Neuralgia
A Study With Lidocaine 5% Medicated Plaster in Patients Suffering From Postherpetic Neuralgia
This study was performed to evaluate the local and systemic safety profile and the analgesic efficacy of long-term treatment with lidocaine 5% medicated plaster (Lido-Patch).
- Trial name
- NCT03765697
- Testing
- Lidocaine 5% medicated plaster
- Volunteers
- 259 people
- Sponsor
- Grünenthal GmbH
Neuralgia, Postherpetic
PH-797804 Versus Placebo For The Treatment Of Neuropathic Pain Associated With Post-Herpetic Neuralgia
This is a proof-of-concept study to determine if PH-797804 reduces neuropathic pain associated with post-herpetic neuralgia. Suitable patients will be randomized to receive either PH-797804 or placebo for 4 weeks, during which…
- Trial name
- NCT00614705
- Testing
- PH-797804
- Where
- 25 sites in Chile, Russia and 4 more
- Volunteers
- 80 people
- Sponsor
- Pfizer
Neuralgia, Postherpetic
RN624 For Pain Of Post-Herpetic Neuralgia
This study will test the efficacy and safety of two doses levels of RN624 versus placebo for the relief of pain caused by post-herpetic neuralgia (PHN).
- Trial name
- NCT00568321
- Testing
- RN624
- Where
- 31 sites in United States
- Volunteers
- 99 people
- Sponsor
- Pfizer
Postherpetic Neuralgia
A Study to Evaluate the Safety and Efficacy of Topically Applied TV 45070 Ointment in Patients With Postherpetic Neuralgia (PHN)
This is a study to evaluate the safety and efficacy of 4% and 8% w/w TV 45070 ointment compared with placebo ointment applied topically and twice daily to the area of PHN pain for 4 weeks in patients with PHN
- Trial name
- (PHN) (NCT02365636)
- Testing
- TV-45070
- Where
- 77 sites in United States
- Volunteers
- 300 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Herpes Zoster, Shingles
ZOSTAVAX™ (Zoster Vaccine Live) Long-term Effectiveness Study (V211-024)
This study will describe the impact of vaccination with ZOSTAVAX™ on the epidemiology of herpes zoster (HZ) in a cohort of vaccinated participants 50 years or age or older, compared to a cohort of unvaccinated participants.
- Trial name
- NCT01600079
- Testing
- ZOSTAVAX™
- Volunteers
- 1,505,647 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Neuralgia, Postherpetic
A Safety and Efficacy Study of AGN-214868 in Patients With Postherpetic Neuralgia
This is a safety and efficacy study of AGN-214868 in patients with postherpetic neuralgia (PHN).
- Trial name
- NCT01678924
- Testing
- AGN-214868
- Where
- 69 sites in United States, Austria and 2 more
- Volunteers
- 280 people
- Sponsor
- Allergan
Herpes Zoster
Burden of Herpes Zoster and Post-herpetic Neuralgia Among People ≥ 50 Years Old in France
The purpose of this study is to assess the burden of Herpes zoster (HZ) and post-herpetic neuralgia (PHN) among people ≥ 50 years old in France, in terms of healthcare resources used, medical direct and indirect costs, as well as…
- Trial name
- NCT02487472
- Testing
- Data collection
- Volunteers
- 106 people
- Sponsor
- GlaxoSmithKline
Neuropathic Pain, Diabetic Peripheral Neuropathy (DPN)
Oral LAT8881 in Neuropathic Pain
This is a randomised, placebo-controlled, double-blind, crossover, phase IIa study to investigate the efficacy and safety of oral LAT8881 in neuropathic pain.
- Conditions
- Neuropathic Pain, Diabetic Peripheral Neuropathy (DPN), Post Herpetic Neuralgia (PHN)
- Trial name
- NCT03865953
- Testing
- LAT8881
- Where
- 6 sites in Australia, United Kingdom
- Volunteers
- 53 people
- Sponsor
- Lateral Pharma Pty Ltd
Neuropathic Pain
Efficacy and Safety of Topical Versus Systemic Treatment in Postherpetic Neuralgia and Diabetic Polyneuropathic Pain
The purpose of this study is to evaluate lidocaine as topical treatment for peripheral neuropathic pain (as stand-alone treatment and in combination with systemic treatment)
- Trial name
- NCT00414349
- Testing
- Topical analgesic, oral intake
- Where
- United Kingdom
- Volunteers
- 431 people
- Sponsor
- Grünenthal GmbH
Neuralgia, Postherpetic
A Long-Term Study To Evaluate Safety And Efficacy Of Pregabalin For Postherpetic Neuralgia
To evaluate the safety of the long-term use of pregabalin.
- Trial name
- NCT00424372
- Testing
- pregabalin
- Where
- 33 sites in Japan
- Volunteers
- 126 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Postherpetic Neuralgia
New Topical Treatment for Continued Pain After Shingles
Shingles is an outbreak of rash or blisters on the skin that is caused by the same virus that causes chicken pox. Some people experience continued pain even after the shingles rash and blisters have healed; this pain is known as…
- Trial name
- NCT00566904
- Testing
- Epikeia coatings with aspirin, Epikeia coatings with lidocaine, Epikeia coatings alone
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Biomedical Development Corporation
Postherpetic Neuralgia
Efficacy and Safety of Eslicarbazepine Acetate as Therapy for Patients With Post-Herpetic Neuralgia
The primary objective of the study is to assess the efficacy of eslicarbazepine acetate (ESL) as therapy for patients with post-herpetic neuralgia.
- Trial name
- NCT00981227
- Testing
- Eslicarbazepine acetate
- Volunteers
- 567 people
- Sponsor
- Bial - Portela C S.A.
Neuralgia, Postherpetic
A Study of the Safety and Efficacy of AGN-214868 in Patients With Postherpetic Neuralgia
This study will evaluate the safety and efficacy of AGN-214868 in patients with postherpetic neuralgia (PHN) - nerve pain.
- Trial name
- NCT01129531
- Testing
- AGN-214868
- Where
- 4 sites in United States, Czechia and 2 more
- Volunteers
- 294 people
- Sponsor
- Allergan
Osteoarthritis, Pain
A SAD Study to Evaluate the Safety, Tolerability and PK/PD of iN1011-N17 in Healthy Volunteers
A First-in-Human, Double-blind, Randomized, Placebo-controlled, Single Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics/Pharmacodynamics of iN1011-N17 after Oral Administration in Healthy Volunteers.
- Conditions
- Osteoarthritis, Pain, Post Herpetic Neuralgia, Neuropathic Pain
- Trial name
- NCT05496205
- Testing
- iN1011-N17
- Where
- Australia
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- iN Therapeutics Co., Ltd.
Post-herpetic Neuralgia
Efficacy and Safety of CNV2197944 Versus Placebo in Patients With Post-herpetic Neuralgia
To investigate the effect of repeat oral dosing of CNV2197944 75 mg tid on the pain experienced in post-herpetic neuralgia (PHN) as measured by changes in PI-NRS after three weeks of treatment compared to the baseline period.
- Trial name
- NCT01848730
- Testing
- CNV2197944
- Where
- South Africa
- Volunteers
- 103 people
- Sponsor
- Convergence Pharmaceuticals
Post Herpetic Neuralgia
Safety And Efficacy Study Of Once Daily Controlled Release Pregabalin In The Treatment Of Patients With Postherpetic Neuralgia
The purpose of the study is to explore the safety and efficacy of a new once a day pregabalin formulation versus placebo for patients with post herpetic neuralgia (Shingles)
- Trial name
- NCT01270828
- Testing
- Pregabalin
- Where
- 146 sites in United States, Bulgaria and 15 more
- Volunteers
- 806 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
PHN - Post-Herpetic Neuritis
A Phase IIb/III Clinical Study to Evaluate the Efficacy and Safety of APC101 in Patients With Postherpetic Neuralgia.
APC101 is developed to provide continuous lidocaine administration over 24 hours and is safe when administered to intact skin. Dispensing from a metered-dose spray pump, APC101 provides once or twice daily flexible dosing options…
- Trial name
- PHN (NCT07599800)
- Testing
- APC101, Control
- Where
- 2 sites in United States, Australia
- Volunteers
- 333 people
- Sponsor
- Andros Pharmaceuticals Co., Ltd.
Neuralgia
Evaluating E2007 (Perampanel) in Patients With Painful Diabetic Neuropathy (PDN) or Post-Herpetic Neuralgia (PHN)
The purpose of this study is to evaluate the safety, tolerability and continued efficacy of perampanel in patients previously enrolled in double-blind, placebo-controlled studies for Painful Diabetic Neuropathy (PDN) or…
- Trial name
- NCT00592904
- Testing
- E2007
- Where
- United States
- Volunteers
- 262 people
- Sponsor
- Eisai Inc.
Diabetic Peripheral Neuropathic Pain (DPN), Postherpetic Neuralgia (PHN)
Pregabalin Treatment Of Peripheral Neuropathic Pain Associated With Diabetic Peripheral NeP (DPN), Postherpetic Neuralgia (PHN), HIV-related NeP (HIV), and Chemotherapy Induced NeP
Management of neuropathic pain associated with diabetic peripheral neuropathy, post-herpetic neuralgia, human immunodeficiency virus-related peripheral neuropathy, and chemotherapy induced peripheral neuropathy.
- Conditions
- Diabetic Peripheral Neuropathic Pain (DPN), Postherpetic Neuralgia (PHN), HIV-related Neuropathic Pain (HIV), Chemotherapy Induced Neuropathic Pain
- Trial name
- NCT00407511
- Testing
- Pregabalin
- Where
- 11 sites in Colombia, Ecuador and 3 more
- Volunteers
- 121 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.